Azilsartan/chlorthalidone combination therapy for blood pressure control

Integrated Blood Pressure Control

Volumn 6, Issue , 2013, Pages 39-48

  Cheng, Judy W M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Azilsartan; Chlorthalidone; Hypertension

Indexed keywords

AZILSARTAN; AZILSARTAN MEDOXOMIL PLUS CHLORTALIDONE; CANDESARTAN HEXETIL PLUS HYDROCHLOROTHIAZIDE; CHLORTALIDONE; EPROSARTAN PLUS HYDROCHLOROTHIAZIDE; FLUCONAZOLE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; KETOCONAZOLE; OLMESARTAN; PLACEBO; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ASTHENIA; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FATIGUE; HEALTH INSURANCE; HUMAN; HYPERTENSION; HYPOTENSION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

EID: 84878394551     PISSN: None     EISSN: 11787104     Source Type: Book Series    
DOI: 10.2147/IBPC.S34792     Document Type: Review

References (32)

1. National Institutes of Health; National Heart, Lung, and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Bethesda, MD, USA: US Department of Health and Human Services; 2004. Available from: http://www.nhlbi.nih.gov/guidelines/hypertension/ jnc7full.pdf. Accessed on August 24, 2011.
2. Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948-954.
3. http://www.cdc.gov [homepage on the Internet]. High Blood Pressure Facts. Centers for Disease Control and Prevention; 2011. Available from: http://www.cdc.gov/bloodpressure/facts.htm. Accessed July 24, 2011.
4. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407.
5. Pharmacy Times. Top 200 Products of 2011 by Total Prescriptions. Plainsboro, NJ, USA: Intellisphere LLC; 2012. Available from: http:// www.pharmacytimes.com/_media/_pdf/Top_200_Drugs_2011_Total_ Rx.pdf. Accessed December 20, 2012.
6. Appendix to Clinical Pharmacology Review: Edarbi®. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceu-tics Review(s). Silver Spring, MD, USA: Food and Drug Administration, 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/n da/2011/200796Orig1s000ClinPharmR.pdf. Accessed July 26, 2011.
7. Takeda Pharmaceuticals USA, Inc. Prescribing Information: Edarbi. Deerfeld: Takeda Pharmaceuticals America, Inc; 2012.Available from: http://www.edarbi.com/. Accessed July 7, 2011.
8. Ojima M, Igata H, Tanaka M, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther. 2011;336(3):801-808.
9. Agrawal M, Swartz R. Acute renal failure. Am Fam Physician. 2000; 61(7):2077-2088.
10. Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinical blood pressure. J Clin Hypertens (Greenwich). 2011;13(2):81-88.
11. White WB, Weber MA, Sica D, et al. Effects of angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stage 1 and 2 hypertension. Hypertension. 2011;57(3):413-420.
12. Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011;13(7):467-472.
13. Bowlus WE, Langford HG. A comparison of the antihypertensive effect of chlorthalidone and hydrochlorothiazide. Clin Pharmacol Ther. 1964;5:708-711.
14. Riess W, Dubach UC, Burckhardt D, Theobald W, Vuillard P, Zimmerli M. Pharmacokinetic studies with chlorthalidone (Hygroton) in man. Eur J Clin Pharmacol. 1977;12(5):375-382.
15. McAinsh J, Bastain W, Young J, Harry JD. Bioavailability in man of atenolol and chlorthalidone from a combination formulation. Biopharm Drug Dispos. 1981;2(2):147-156.
16. Collste P, Garle M, Rawlins MD, Sjöqvist F. Interindividual differences in chlorthalidone concentration in plasma and red cells of man after single and multiple doses. Eur J Clin Pharmacol. 1976;9(4):319-325.
17. Bengtsson C, Johnsson G, Sannerstedt R, Werko L. Effect of different doses of chlorthalidone on blood pressure, serum potassium, and serum urate. Br Med J. 1975;1(5951):197-199.
18. Takeda Pharmaceuticals USA, Inc. Prescribing Information: Edarbyclor. Deerfeld: Takeda Pharmaceuticals America, Inc; 2012. Available from: http://www.edarbi.com/. Accessed January 3, 2013.
19. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82(5):1616-1628.
20. Dorsch M P, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57(4):689-694.
21. Sica D, Bakris GL, White WB, et al. Blood pressure lowering effcacy of the fxed dose combination of azilsartan and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012;14(5):284-292.
22. Cushman WC, Bakris GL, White WB, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorthiazide in stage 2 systolic hypertension. Hypertension. 2012;60(2):310-318.
23. Bakris GL, Sica D, White WB, et al. Antihypertensive effcacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012;125(12):1229. e1-1229. e10.
24. Divisional Memo: Azilsartan medoxomil (Edarbi) for hypertension. Center for Drug Evaluation and Research. Medical Review(s). Silver Spring, MD, USA: Food and Drug Administration, 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/ nda/2011/200796Orig1s000MedR.pdf. Accessed April 12, 2013.
25. Addendum to Clinical Review of NDA 202-331 (Edarbyclor®). Center for Drug Evaluation and Research. Medical Review(s). Silver Spring, MD, USA: Food and Drug Administration, 2011. Available from: http://www. accessdata.fda.gov/drugsatfda_docs/nda/2011/202331Orig1s000MedR. pdf. Accessed January 3, 2013.
26. Medication Average Wholesale Price. Thomson Reuters Micromedex Clinical Evidence Solutions [Internet]. Thomson Reuters; c2011. RED BOOK Drug References; c2011 [cited July 8, 2011]. Available from: http://thomsonreuters.com/products_services/healthcare/healthcare_ products/clinical_deci_support/micromedex_clinical_evidence_sols/ med_safety_solutions/red_book/. Accessed April 13, 2013.
27. Cushman WC, Ford CE, Cutler JA, et al; ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393-404.
28. Dahlöf B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359(9311):995-1003.
29. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-2816.
30. Dahlöf B, Sever PS, Poulter N, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofumethiaizde as required in the Ango-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005; 366(9489): 895-906.
31. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049-2051.
32. Corrao G, Nicotra F, Parodi A, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension. 2011;58(4):566-572.